Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma

NCT05131698 is registered in ClinicalTrials.gov with Cancer Hospital of Guangxi Medical University as lead sponsor.

NCT NCT05131698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05131698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma
Lead sponsor
Cancer Hospital of Guangxi Medical University
Phase
Phase 1
Overall status
Unknown status
Start date
March 1, 2021
Completion date
July 5, 2024
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced unresectable hepatocellular carcinoma, lenvatinib, tace, tislelizumab